Bachem Holding AG
BANB
Rang in aandelen
#2516
Bachem Holding AG serves pharmaceutical and biotechnology companies globally,... Bachem Holding AG serves pharmaceutical and biotechnology companies globally, providing products crucial for research, clinical development, and commercial use. The company's primary focus is on the design, manufacturing, and regulatory support for peptide active pharmaceutical ingredients (APIs), specifically targeting novel peptide and oligonucleotide chemical entities (NCEs). Additionally, Bachem offers commercially available NCEs and generic compounds. Its comprehensive service portfolio includes project management, quality assurance and regulatory guidance, analytical testing, production adhering to Good Manufacturing Practices (GMP), manufacturing for research purposes, and expertise in supply chain and vertical integration. Established in 1971, Bachem Holding AG is headquartered in Bubendorf, Switzerland, and functions as a subsidiary of Ingro Finanz AG.
Aandeelprijs
$100.60
Marktkapitalisatie
$7.54B
Verandering (1 dag)
-1.49%
Verandering (1 jaar)
49.53%
Land
CH
Handel Bachem Holding AG (BANB)
Categorie
Healthcare
Omzet van Bachem Holding AG (BANB)
Omzet in Oct 2026 TTM: 0
Volgens de laatste financiële rapporten van Bachem Holding AG bedraagt de huidige omzet van het bedrijf (TTM) 0. In 2026 behaalde het bedrijf een omzet van 0 gelijk aan de omzet in het jaar 2026, die 0 bedroeg. De omzet is het totale bedrag aan inkomsten dat een bedrijf genereert door de verkoop van goederen of diensten. In tegenstelling tot de winst worden er geen kosten afgetrokken.
Omzetgeschiedenis van Bachem Holding AG van 2002 tot 2026
Omzet aan het einde van elk jaar
| Jaar | Omzet | Wijzigen |
|---|---|---|
| 2025 | $875.88M | 30.72% |
| 2024 | $670.05M | -2.39% |
| 2023 | $686.47M | 19.36% |
| 2022 | $575.15M | 4.20% |
| 2021 | $551.97M | 23.34% |
| 2020 | $447.51M | 38.00% |
| 2019 | $324.29M | 12.93% |
| 2018 | $287.17M | 6.98% |
| 2017 | $268.42M | 15.53% |
| 2016 | $232.34M | 11.33% |
| 2015 | $208.69M | 12.70% |
| 2014 | $185.17M | -3.20% |
| 2013 | $191.29M | 11.30% |
| 2012 | $171.87M | 10.72% |
| 2011 | $155.22M | -5.12% |
| 2010 | $163.59M | -7.04% |
| 2009 | $175.99M | -3.60% |
| 2008 | $182.56M | 4.04% |
| 2007 | $175.47M | 24.55% |
| 2006 | $140.88M | 20.66% |
| 2005 | $116.75M | -10.21% |
| 2004 | $130.03M | 11.21% |
| 2003 | $116.92M | 7.90% |
| 2002 | $108.36M | 0.00% |
Omzet van vergelijkbare bedrijven of concurrenten
| Bedrijf | Omzet | Omzetverschil | Land |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| $6.02B | - |
NL
|
|
| - | - |
CH
|
